<DOC>
	<DOC>NCT02254941</DOC>
	<brief_summary>The purpose of this study is to evaluate, in terms of overall survival, the benefit of monoclonal antibodies in the start time of the diagnosis of advanced disease or administer a deferred basis after progression to treatment with chemotherapy alone.</brief_summary>
	<brief_title>Observational Study to Evaluate the Use of Targeted Therapies in Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Patients diagnosed with metastatic colorectal cancer with biopsy positive for adenocarcinoma. ECOG PS02. Who have not received prior chemotherapy treatment for metastatic disease. Measurable or evaluable disease. No previous surgery for metastatic disease. Surgery for metastasis allowed after inclusion in the study aftercare at the discretion of investigadors. Chemotherapy treatment with doublets (CAPOX, FOLFOX, FOLFIRI) Patients older than 70 years with frailty criteria.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Metastatic Colon Cancer</keyword>
	<keyword>Monoclonal antibodies</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>First line</keyword>
</DOC>